ANIK — Anika Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 898437 ·
Last close
$14.89
Market Cap
$198.12M
52W High
$16.24
52W Low
$11.92
ADV30
110,540
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 29,612,000 | 18,997,000 | -5,488,000 | -5,056,000 | 179,387,000 | 41,020,000 | 45,486,000 |
| Dec 2025 | 30,615,000 | 19,179,000 | 646,000 | 292,000 | 190,270,000 | 57,481,000 | 46,805,000 |
| Sep 2025 | 27,817,000 | 15,584,000 | -3,233,000 | -2,329,000 | 189,437,000 | 57,990,000 | 42,632,000 |
| Jun 2025 | 28,219,000 | 14,363,000 | -4,180,000 | -3,970,000 | 187,682,000 | 53,167,000 | 40,010,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$6,472,000
Investing CF
$-3,312,000
Financing CF
$-15,460,000
CapEx
$-5,433,000
Dividends Paid
—
Buybacks
$-14,204,000
EPS Diluted TTM
$-0.79
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$55,731,000
Inventory
$22,838,000
Receivables
$25,768,000
ST Investments
—
EBIT TTM
$-12,255,000
Pretax Income TTM
$-10,259,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$116,263,000
EBITDA
$-6,860,000
Free Cash Flow
$6,358,625
Enterprise Value
$182,703,680
Total Cash
$41,020,000
Total Debt
$25,736,000
Shares Out
13,305,624
Trailing EPS
$-0.79
Book Value
$10.03
ROE
-7.8%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 112,819,000 | -11,051,000 | -10,880,000 | 190,270,000 | 46,805,000 | — | 11,188,000 |
| Dec 2024 | 119,907,000 | -5,101,000 | -56,385,000 | 202,740,000 | 48,751,000 | — | 5,403,000 |
| Dec 2023 | 120,792,000 | 844,000 | -82,667,000 | 270,632,000 | 58,367,000 | — | -1,788,000 |
| Dec 2022 | 113,827,000 | 3,670,000 | -14,859,000 | 349,128,000 | 63,565,000 | — | 4,409,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | $197.76M | $3.22 | — |
| EMBC | Embecta Corp. | $196.97M | $3.32 | — |
| KRMD | KORU Medical Systems, Inc. | $192.92M | $4.20 | — |
| INFU | InfuSystem Holdings, Inc | $191.93M | $9.51 | — |
| STXS | Stereotaxis, Inc. | $190.59M | $1.95 | — |
News headlines (Yahoo Finance, 1h cache)
President of Anika Therapeutics Picks Up 51% More Stock
2026-05-03 13:36 · Yahoo
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter
2026-04-30 20:43 · Yahoo
Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary
2026-04-29 16:50 · Yahoo
Anika Therapeutics Q1 Earnings Call Highlights
2026-04-29 14:20 · Yahoo
Anika Reports First Quarter 2026 Financial Results
2026-04-29 11:05 · Yahoo
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
2026-04-16 11:30 · Yahoo
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
2026-04-15 20:01 · Yahoo
Telix Strengthens Board with Additional Director Appointments
2026-04-08 22:44 · Yahoo
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
2026-04-07 19:35 · Yahoo
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-03 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.